Share-based Payment Arrangement, Expense in USD of Aptevo Therapeutics Inc. from Q3 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aptevo Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2015 to Q1 2025.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $180K, a 75% decline year-over-year.
  • Aptevo Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $530K, a 73.5% decline year-over-year.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1.07M, a 51.3% decline from 2023.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.19M, a 21.7% increase from 2022.
  • Aptevo Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.8M, a 9.68% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aptevo Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $530K $180K -$539K -75% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $1.07M -$72K -$430K -120% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025
Q3 2024 $1.5M $149K -$306K -67.3% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024
Q2 2024 $1.81M $273K -$192K -41.3% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024
Q1 2024 $2M $719K -$196K -21.4% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 $2.19M $358K $0 0% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025
Q3 2023 $2.19M $455K +$96K +26.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 $2.1M $465K -$19K -3.93% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $2.12M $915K +$314K +52.2% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $1.8M $358K +$180K +101% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 $1.62M $359K +$40K +12.5% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $1.58M $484K -$88K -15.4% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 $1.67M $601K +$27K +4.7% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 $1.64M $178K -$20K -10.1% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 $1.66M $319K -$24K -7% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $1.69M $572K +$271K +90% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 $1.42M $574K +$161K +39% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 $1.26M $198K -$71K -26.4% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022
Q3 2020 $1.33M $343K +$9K +2.7% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 $1.32M $301K -$100K -24.9% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 $1.42M $413K -$181K -30.5% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021
Q4 2019 $1.6M $269K -$224K -45.4% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 $1.82M $334K -$147K -30.6% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 $1.97M $401K -$48K -10.7% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 $2.02M $594K -$123K -17.2% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020
Q4 2018 $2.14M $493K -$573K -53.8% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2020
Q3 2018 $2.71M $481K -$559K -53.8% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 $3.27M $449K -$651K -59.2% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $3.92M $717K -$961K -57.3% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $4.88M $1.07M +$1.68M 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019
Q3 2017 $3.2M $1.04M -$293K -22% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 $3.49M $1.1M +$700K +175% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $2.79M $1.68M -$1.02M -37.7% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 $3.81M -$617K 01 Oct 2016 31 Dec 2016 10-K 13 Mar 2018
Q3 2016 $1.33M +$1.05M +374% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 $400K 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017
Q1 2016 $2.69M 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q3 2015 $281K 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016

Aptevo Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.07M -$1.12M -51.3% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025
2023 $2.19M +$391K +21.7% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025
2022 $1.8M +$159K +9.68% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 $1.64M +$388K +30.9% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 $1.26M -$343K -21.5% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022
2019 $1.6M -$542K -25.3% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 $2.14M -$2.74M -56.2% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2020
2017 $4.88M +$1.08M +28.2% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019
2016 $3.81M +$2.7M +244% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2018
2015 $1.11M 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.